Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1847)	6/9/2005 8:44:39 AM
From: arnie h	Read Replies (1) \| Respond to of 2173

From a recent interview with CEO of Lilly as reported by Business Week. Q: Lilly has had some big-selling diabetes products in the past. Are these new ones likely to be as big? A: I don't want to make sales forecasts, but, for Byetta, we're talking about a very important drug. Diabetes is a progressive disease. Eventually, a lot of people end up having to take insulin. We see Byetta as being used prior to getting to insulin. Of the people getting treated for diabetes today, 6 million are taking oral products. We know that two-thirds of patients on oral therapy fail to meet the target level for good control of blood glucose. So, two-thirds of those 6 million are the target patients for Byetta. And in the future, we think we're going to be able to show also that it works with another 2 million to 3 million patients. ______________ In the meantime AMLN seems to be blowing a tire. Fascinating that the price was in the 20's for a long period and is now heading south after the 2 FDA approvals.